TICKERNERD
Menu
WALDWALDConsumer Defensive · Household & Personal Products

WALD Stock Forecast: Waldencast plc Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.29
−4.44% on the day

The 3 Wall Street analysts covering Waldencast plc hold a median 12-month price target of $2.5 — +93.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$166.7M
Ticker Nerd rank
63 / 100
Median analyst target
$2.50
Analysts covering
3
Total return, dividends reinvested
1W
−4.4%
1M
−28.3%
YTD
−31.4%
1Y
−21.6%
From 52W high
−58.1%
From 52W low
+69.1%
$0.76
$3.08
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

WALD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Waldencast plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
63 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
96
Issuance
74
Value
74
Volatility
73
Size
70
Quality
65
Revisions
43
Growth
22
Momentum
10

Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (10): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

WALD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on WALD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50$3.00Oct 25Jan 26Apr 26Jul 26WALDHigh $3.00Median $2.50Low $1.60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $1.60Median $2.50High $3.00

The green dot is the last close — the median target sits +93.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 June 2026Canaccord GenuityMaintainsBuy$2.00 → $3.00
16 Mar 2026Canaccord GenuityMaintainsBuy—
16 Mar 2026Telsey Advisory GroupMaintainsMarket Perform—
14 Jan 2026JefferiesAssumesBuy$2.00
25 Nov 2025Canaccord GenuityMaintainsBuy—
25 Nov 2025Telsey Advisory GroupDowngradeMarket Perform—
20 Aug 2025Telsey Advisory GroupMaintainsOutperform—
13 Aug 2025Telsey Advisory GroupMaintainsOutperform—
15 May 2025Canaccord GenuityMaintainsBuy—
15 May 2025Telsey Advisory GroupMaintainsOutperform—
6 May 2025Telsey Advisory GroupMaintainsOutperform—
22 Apr 2025Alliance Global PartnersInitiatesBuy—
20 Mar 2025Telsey Advisory GroupMaintainsOutperform—
19 Mar 2025DA DavidsonMaintainsBuy—
19 Mar 2025Telsey Advisory GroupMaintainsOutperform—
11 Mar 2025Telsey Advisory GroupMaintainsOutperform—
16 Dec 2024TD CowenInitiatesHold—
4 Dec 2024DA DavidsonMaintainsBuy—
22 Nov 2024Canaccord GenuityMaintainsBuy—
22 Nov 2024Telsey Advisory GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. WALD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

WALD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Waldencast plc (WALD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.6×

Cheaper than 79% of US stocks

Price / book
0.3×

Cheaper than 88% of US stocks

EV / EBITDA
−53.7×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
−1.7%

Higher than 25% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−22.5%

Higher than 21% of US stocks

Net margin
−84.4%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−40.3%

Higher than 24% of US stocks

Return on assets
−4.7%

Higher than 32% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

WALD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHousehold & Personal Products
CompanyMarket capTKN rank
WALDWaldencast plc$166.7M
63
NUSNu Skin Enterprises, Inc.$233.1M
66
ACUAcme United Corp.$233.7M
99
SKINSkinhealth Systems, Inc.$83.5M
79
SLSNSolesence, Inc.$67.1M
29
MAGNMagnera Corp.$439.3M
42
HNSTThe Honest Co., Inc.$568.0M
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Waldencast plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest WALD news & analysis

Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint

GlobeNewsWire · 30 July 2026positive

Waldencast plc announced it has completed the sale of its Obagi Medical dermatological skincare business to Bridgepoint in a transaction valued at up to $460 million, subject to customary adjustments.

Why it matters — The sale represents a major step in Waldencast's strategy to strengthen its balance sheet and focus resources on accelerating the global growth of its remaining brand, Milk Makeup.

FAQ

Frequently asked questions about WALD stock

What is the WALD stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Waldencast plc have a median 12-month price target of $2.5, with estimates ranging from $1.6 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is WALD stock a buy right now?

Of the 3 analysts covering Waldencast plc, 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Waldencast plc 63 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank WALD?

As at 22 Aug 2026, Waldencast plc ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).

Will WALD stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +93.8% from the last close, and Ticker Nerd's factor model ranks Waldencast plc 63 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the WALD stock forecast for 2030?

No analyst covering Waldencast plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for WALD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.6 to $3 over the next 12 months.

How has WALD stock performed over the past year?

Waldencast plc returned -21.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Waldencast plc do?

Waldencast plc operates as a beauty and wellness company focused on investing in and building businesses within the consumer sector. Waldencast aims to develop a dynamic portfolio of enduring, high-growth companies that address the evolving needs and preferences of consumers in the beauty and wellness industries.

What is the latest news on WALD?

The most recent item we track (GlobeNewsWire, 30 July 2026): "Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint". Waldencast plc announced it has completed the sale of its Obagi Medical dermatological skincare business to Bridgepoint in a transaction valued at up to $460 million, subject to customary adjustments.

Company

About Waldencast plc.

Waldencast plc operates as a beauty and wellness company focused on investing in and building businesses within the consumer sector. Waldencast aims to develop a dynamic portfolio of enduring, high-growth companies that address the evolving needs and preferences of consumers in the beauty and wellness industries. The company seeks to identify and nurture emerging brands, leveraging its strategic expertise, industry relationships, and financial resources to foster growth and innovation. Waldencast places significant emphasis on sustainability and consumer-centric strategies, addressing global trends towards more conscious consumption and personal well-being. As part of its operational model, Waldencast collaborates with entrepreneurs and industry experts to scale businesses efficiently, often incorporating sustainable practices and innovative technology into its brands. In the financial market, Waldencast plays a crucial role by merging investment capabilities with industry insights, catering to businesses looking to expand their market presence and impact. Its approach enables the discovery and promotion of new brands into steadily growing segments of the beauty and wellness sectors, highlighting its importance as a catalyst for growth and innovation in these fields.

CEO Mr. Felipe Dutra · 367 employees · United Kingdom · https://www.waldencast.com